[go: up one dir, main page]

GB0406279D0 - Therapeutic compounds - Google Patents

Therapeutic compounds

Info

Publication number
GB0406279D0
GB0406279D0 GBGB0406279.0A GB0406279A GB0406279D0 GB 0406279 D0 GB0406279 D0 GB 0406279D0 GB 0406279 A GB0406279 A GB 0406279A GB 0406279 D0 GB0406279 D0 GB 0406279D0
Authority
GB
United Kingdom
Prior art keywords
rsv
therapeutic compounds
diluent
inhibitor
found
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0406279.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrow Therapeutics Ltd
Original Assignee
Arrow Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrow Therapeutics Ltd filed Critical Arrow Therapeutics Ltd
Priority to GBGB0406279.0A priority Critical patent/GB0406279D0/en
Publication of GB0406279D0 publication Critical patent/GB0406279D0/en
Priority to ES05728747T priority patent/ES2331479T3/en
Priority to BRPI0507652-8A priority patent/BRPI0507652A/en
Priority to PT05728747T priority patent/PT1727551E/en
Priority to CA002557931A priority patent/CA2557931A1/en
Priority to PL05728747T priority patent/PL1727551T3/en
Priority to AT05728747T priority patent/ATE442145T1/en
Priority to PCT/GB2005/001029 priority patent/WO2005089771A1/en
Priority to DE602005016532T priority patent/DE602005016532D1/en
Priority to JP2007503412A priority patent/JP2007529491A/en
Priority to RU2006136881/15A priority patent/RU2006136881A/en
Priority to AU2005224159A priority patent/AU2005224159B2/en
Priority to KR1020067021651A priority patent/KR20070009630A/en
Priority to EP05728747A priority patent/EP1727551B1/en
Priority to CNB2005800089207A priority patent/CN100496499C/en
Priority to DK05728747T priority patent/DK1727551T3/en
Priority to US10/593,382 priority patent/US20070185096A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.
GBGB0406279.0A 2004-03-19 2004-03-19 Therapeutic compounds Ceased GB0406279D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB0406279.0A GB0406279D0 (en) 2004-03-19 2004-03-19 Therapeutic compounds
US10/593,382 US20070185096A1 (en) 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein
DE602005016532T DE602005016532D1 (en) 2004-03-19 2005-03-18 PHARMACEUTICAL COMPOSITION WITH A BENZODIA EINS
RU2006136881/15A RU2006136881A (en) 2004-03-19 2005-03-18 PHARMACEUTICAL COMPOSITION CONTAINING A DERIVATIVE BENZODIAZEPINE AND RSV Fusion Protein Inhibitor
PT05728747T PT1727551E (en) 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and a inhibitor of the rsv fusion protein
CA002557931A CA2557931A1 (en) 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and a inhibitor of the rsv fusion protein
PL05728747T PL1727551T3 (en) 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and a inhibitor of the rsv fusion protein
AT05728747T ATE442145T1 (en) 2004-03-19 2005-03-18 PHARMACEUTICAL COMPOSITION CONTAINING A BENZODIAZEPINE DERIVATIVE AND AN RSV FUSION PROTEIN INHIBITOR
PCT/GB2005/001029 WO2005089771A1 (en) 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and a inhibitor of the rsv fusion protein
ES05728747T ES2331479T3 (en) 2004-03-19 2005-03-18 PHARMACEUTICAL COMPOSITION THAT INCLUDES A BENZODIAZEPIN DERIVATIVE AND AN INHIBITOR OF THE RSV FUSION PROTEIN.
JP2007503412A JP2007529491A (en) 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and an RSV fusion protein inhibitor
BRPI0507652-8A BRPI0507652A (en) 2004-03-19 2005-03-18 pharmaceutical compositions comprising a benzoidiazepine derivative and an rsv fusion protein inhibitor
AU2005224159A AU2005224159B2 (en) 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and a inhibitor of the RSV fusion protein
KR1020067021651A KR20070009630A (en) 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of an RX fusion protein
EP05728747A EP1727551B1 (en) 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and a inhibitor of the rsv fusion protein
CNB2005800089207A CN100496499C (en) 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the RSV fusion protein
DK05728747T DK1727551T3 (en) 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the RSV fusion protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0406279.0A GB0406279D0 (en) 2004-03-19 2004-03-19 Therapeutic compounds

Publications (1)

Publication Number Publication Date
GB0406279D0 true GB0406279D0 (en) 2004-04-21

Family

ID=32118066

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0406279.0A Ceased GB0406279D0 (en) 2004-03-19 2004-03-19 Therapeutic compounds

Country Status (17)

Country Link
US (1) US20070185096A1 (en)
EP (1) EP1727551B1 (en)
JP (1) JP2007529491A (en)
KR (1) KR20070009630A (en)
CN (1) CN100496499C (en)
AT (1) ATE442145T1 (en)
AU (1) AU2005224159B2 (en)
BR (1) BRPI0507652A (en)
CA (1) CA2557931A1 (en)
DE (1) DE602005016532D1 (en)
DK (1) DK1727551T3 (en)
ES (1) ES2331479T3 (en)
GB (1) GB0406279D0 (en)
PL (1) PL1727551T3 (en)
PT (1) PT1727551E (en)
RU (1) RU2006136881A (en)
WO (1) WO2005089771A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0406282D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
KR20090040478A (en) 2006-08-24 2009-04-24 노파르티스 아게 2- (pyrazin-2-yl) -thiazole and 2- (1H-pyrazol-3-yl) -thiazole derivatives, and stearoyl-COA desaturase for the treatment of metabolism, cardiovascular and other disorders ( Related Compounds as Scd) Inhibitors
CA2662574A1 (en) 2006-09-22 2008-03-27 Novartis Ag Heterocyclic organic compounds
WO2008074835A1 (en) 2006-12-20 2008-06-26 Novartis Ag 2-substituted 5-membered heterocycles as scd inhibitors
AU2009244504A1 (en) * 2008-05-05 2009-11-12 Amgen Inc. Urea compounds as gamma secretase modulators
US9556236B1 (en) 2012-11-29 2017-01-31 University Of South Florida Compositions and methods for treating respiratory syncytial virus infection
CN108200760B (en) * 2015-07-22 2022-04-01 英安塔制药有限公司 Benzodiazepine derivatives as RSV inhibitors
CN108699077B (en) 2016-01-15 2021-03-02 英安塔制药有限公司 Heterocyclic compounds as RSV inhibitors
GB201613942D0 (en) * 2016-08-15 2016-09-28 Univ Of Durham The An antimicrobial compound
WO2018129287A1 (en) 2017-01-06 2018-07-12 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as rsv inhibitors
IL268737B2 (en) * 2017-02-16 2024-02-01 Enanta Pharm Inc Processes for the preparation of benzodiapine derivatives
US10752598B2 (en) 2017-06-07 2020-08-25 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as RSV inhibitors
US10851115B2 (en) 2017-06-30 2020-12-01 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019046364A1 (en) * 2017-08-29 2019-03-07 Emory University Inhibitors of rsv replication and applications thereof
MX2020004084A (en) * 2017-09-29 2020-07-29 Enanta Pharm Inc Combination pharmaceutical agents as rsv inhibitors.
CA3080138A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
US10975094B2 (en) 2018-04-11 2021-04-13 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
CA3133300A1 (en) 2019-03-18 2020-09-24 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
US11179400B2 (en) 2019-04-09 2021-11-23 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
GB201911944D0 (en) 2019-08-20 2019-10-02 Reviral Ltd Pharmaceutical compounds
PH12022550783A1 (en) 2019-10-04 2023-07-31 Enanta Pharm Inc Antiviral heterocyclic compounds
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
GB201915273D0 (en) * 2019-10-22 2019-12-04 Reviral Ltd Pharmaceutical compounds
UY39032A (en) 2020-01-24 2021-07-30 Enanta Pharm Inc HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US11945830B2 (en) 2021-02-26 2024-04-02 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324794A (en) * 1980-08-26 1982-04-13 Research Triangle Institute Inhibition of respiratory syncytial virus-induced cell fusion by amidino compounds
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
EP0491218A1 (en) * 1990-12-17 1992-06-24 F. Hoffmann-La Roche Ag Benzodiazepinones
US6489338B2 (en) * 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
US6919331B2 (en) * 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
WO2003049688A2 (en) * 2001-12-10 2003-06-19 Bristol-Myers Squibb Company Bis hydrochloride monohydrate salt of rsv fusion inhibitor
AU2003267587B2 (en) * 2002-09-20 2010-05-20 Arrow Therapeutics Limited Benzodiazepine derivatives and pharmaceutical compositions containing them
GB0406282D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds

Also Published As

Publication number Publication date
US20070185096A1 (en) 2007-08-09
DK1727551T3 (en) 2009-12-14
CN1933841A (en) 2007-03-21
PL1727551T3 (en) 2010-02-26
CA2557931A1 (en) 2005-09-29
WO2005089771A1 (en) 2005-09-29
EP1727551B1 (en) 2009-09-09
BRPI0507652A (en) 2007-07-10
RU2006136881A (en) 2008-04-27
EP1727551A1 (en) 2006-12-06
ATE442145T1 (en) 2009-09-15
ES2331479T3 (en) 2010-01-05
JP2007529491A (en) 2007-10-25
DE602005016532D1 (en) 2009-10-22
PT1727551E (en) 2009-10-08
AU2005224159A1 (en) 2005-09-29
CN100496499C (en) 2009-06-10
KR20070009630A (en) 2007-01-18
AU2005224159B2 (en) 2009-05-21

Similar Documents

Publication Publication Date Title
GB0406279D0 (en) Therapeutic compounds
HK1098372A1 (en) Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein
AU2003264038A1 (en) Combination pharmaceutical agents as inhibitors of hcv replication
MXPA05002871A (en) Benzodiazepine derivatives and pharmaceutical compositions containing them.
WO2006128184A3 (en) Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
GEP20135791B (en) Use of dipeptidyl peptidase inhibitors
CA2504735A1 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004050022A8 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2002044183A3 (en) Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
GEP20053675B (en) Pyridazinone Aldose Reductase Inhibitors
WO2007139856A3 (en) Heterobicyclic metalloprotease inhibitors
WO2005044195A3 (en) Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
UA84266C2 (en) Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyroolidon as excipient, processes for the preparation and use thereof
HUS1200030I1 (en) Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv and method for their preparation and pharmaceutical compositions containing the compounds
TW200510375A (en) New compounds
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
MY144659A (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
MXPA05010521A (en) Biphenyl carboxylic amide p38 kinase inhibitors.
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
AU2001230395A1 (en) Use of cox-2 inhibitors as gastroprokinetics
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
AU2002256775A1 (en) Therapeutic method for inducing tolerance
AU2003287388A1 (en) Inhibition of hiv-1 replication

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)